Lupus Low Disease Activity State is Associated with Reduced Direct Healthcare Costs in Patients with Systemic Lupus Erythematosus.
Treat to target endpoints for Systemic Lupus Erythematosus (SLE) have been assessed for impact on damage accrual and flare, but whether they impact on the high healthcare utilization and costs in SLE has not been studied. We hypothesized that the recently described lupus low disease activity state (LLDAS) would be associated with reduced healthcare cost. Data from a single tertiary hospital longitudinal SLE cohort were assessed. Baseline demographics, disease activity (SLE Disease Activity Index (SLEDAI)-2K; physician global assessment, PGA; and, flare index) and medication use were evaluated, and direct healthcare utilization and cost data were obtained from hospital information systems. LLDAS was defined as previously published: briefly, SLEDAI-2K ≤ 4 with no new activity, PGA ≤ 1, prednisolone ≤7.5mg/day, and optimal standard immunosuppressive agents. Analysis was performed using multivariable linear regression. Two hundred SLE patients, contributing 357.8 person-years observation, were included. A history of lupus nephritis was present in 42%, and damage (SLICC-ACR damage index >0) was present at study commencement in 57.3%. The mean (±standard deviation) annual direct medical cost per patient was US$7,413 (±US$13,133)/year. In multivariable analysis, increased cost was associated with the presence of baseline organ damage (41.7% increase, P=0.009), and corticosteroid use (>7.5-15 mg/day, 55.7% increase, P=0.02; > 15 mg/day, 202% increase, P<0.001). In contrast, spending ≥50% of the observation period in LLDAS was associated with a 25.9% reduction in annual direct medical cost (p=0.04). Greater time spent in LLDAS was associated with significantly reduced direct hospital healthcare costs among patients with SLE. This article is protected by copyright. All rights reserved.